HORMONE THERAPY WITH USAGE OF AGONISTS AND ANTAGONISTS OF LUTEINIZING HORMONE RELEASING HORMONE IN PATIENTS WITH PROSTATE CANCER
https://doi.org/10.17709/2409-2231-2014-1-1-69-73
Abstract
Prostate cancer (PC) is one of the most actual problems of modern oncourology. Hormone therapy (HT) using medical castration is the main method of treatment of patients with metastatic PC. HT with usage of the new class of drugs that block the receptors for luteinizing hormone releasing hormone (LHRH) is a promising and effective method of castration therapy that has a number of significant advantages over the use of analogues LHRH. This article presents a
review of studies that compared the effectiveness and side effects of HT using antagonists and analogues LHRH.
About the Authors
K. M. Nyushko
Moscow Oncology Institute of the Hertsen FMRC MH RF (Moscow, Russian Federation) 3, 2 B otkinskiy proezd, 125284, Russian Federation, Moscow
Russian Federation
Russian Federation
PhD, senior researcher of oncourological department of Moscow Oncology Institute of the Hertsen FMRC MH RF 3, 2 Botkinskiy proezd, 125284, Russian Federation, Moscow Теl: +7 (495) 945‑15‑72
A. A. Krasheninnikov
Moscow Oncology Institute of the Hertsen FMRC MH RF (Moscow, Russian Federation) 3, 2 B otkinskiy proezd, 125284, Russian Federation, Moscow
Russian Federation
Russian Federation
PhD, researcher of oncourological department of P.A. Herzen Moscow Research Oncological Institute of the P.A. Herzen Federal Medical Research Center of Ministry of Health of Russian Federation
M. P. Golovaschenko
Moscow Oncology Institute of the Hertsen FMRC MH RF (Moscow, Russian Federation) 3, 2 B otkinskiy proezd, 125284, Russian Federation, Moscow
Russian Federation
Russian Federation
junior researcher of oncourological department of P.A. Herzen Moscow Research Oncological Institute of the P.A. Herzen Federal Medical Research Center of Ministry of Health of Russian Federation
A. D. Kaprin
Hertsen FMRC MH RF (Obninsk, Russian Federation) 4, st. Korolev, 249036, Russian Federation, Kaluga region, Obninsk
Russian Federation
Russian Federation
MD, professor, corresponding member of RAS, general director of the P.A. Herzen Federal Medical Research Center of Ministry of Health of Russian Federation
References
1. Sostojanie onkologicheskoj pomoshhi naseleniju Rossii v 2012 godu [Kniga]//Pod red. A. D. Kaprina V. V. Starinskogo, G. V. Petrovoj. – M: FGBU «MNIOI im. P. A. Gercena» Minzdrava Rossii, 2013. – str. 128.
2. Huggins C, Hoges C. V. Studies on prostate cancer. The effect of castration [Journal]//Cancer Res. – 1941. – pp. 385–402.
3. Malkowicz S. B. The role of diethylstilbestrol in the treatment of prostate cancer [Journal]//Urology. – 2001. – Vol. 58. – pp. 108–13.
4. Alekseev B.Ja., Njushko K. M. Gormonal’naja terapija bol’nyh rakom predstatel’noj zhelezy [Zhurnal]//Onkourologija. – 2007 g. – T. 3. – str. 57–62.
5. Kaisary A. V., Tyrrell C. J., Peeling W. B. et al. Comparison of LHRH analogue with orchiectomy in patients with metastatic prostatic carcinoma [Journal]//Br J Urol. – 1991. – Vol. 67. – pp. 502–8.
6. Rusakov I. G., Alekseev B.Ja., Njushko K. M. Gormonal’naja terapija preparatom lejprorelin (ljukrin-depo®) u bol’nyh rakom predstatel’noj zhelezy [Zhurnal]//Onkourologija. – 2009 g. – T. 3. – str. 56–60.
7. Alekseev B.Ja., Njushko K. M., Vorob’ev N. V. i dr. Chastota i lokalizacija metastazov v limfaticheskih uzlah pri vypolnenii radikal’noj prostatjektomii i rasshirennoj tazovoj limfadenjektomii u bol’nyh rakom predstatel’noj zhelezy [Zhurnal]//Onkourologija. – 2012 g. – T. 1. – str. 77–82.
8. Alekseev B.Ja., Njushko K. M. Rasshirennaja tazovaja limfadenjektomija pri hirurgicheskom lechenii raka predstatel’noj zhelezy [Zhurnal]//Vrach. – 2010 g. – T. 11. – str. 63–64.
9. Alekseev B.Ja., Njushko K. M. Ad#juvantnaja gormonal’naja terapija kak metod radikal’nogo lechenija u bol’nyh mestno-rasprostranennym rakom predstatel’noj zhelezy [Zhurnal]//Onkourologija. – 2007 g. – T. 2. – str. 61–63.
10. Alekseev B.Ja., Njushko K. M. Radikal’naja prostatjektomija s rasshirennoj tazovoj limfadenjektomiej i ad#juvantnaja gormonal’naja terapija u bol’nyh limfogenno-disseminirovannym rakom predstatel’noj zhelezy [Zhurnal]//Onkourologija. – 2011 g. – T. 3. – str. 118–121.
11. Keating N. L., O’Malley A. J., Freedland S. J. et al. Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer [Journal]// J Natl Cancer Inst. – 2010. – Vol. 102. – pp. 39–46.
12. Bubley G. J. Is the flare phenomenon clinically significant? [Journal]//Urology. – 2001. – Vol. 58. – pp. 5–9.
13. Bertaglia V., Tucci M., Fiori C. et al. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer [Journal]//Clin Genitourin Cancer. – 2013. – Vol. 11. – pp. 325–330.
14. Rick F. G., Block N. L., Schally A. V. An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer [Journal]//Onco Targets Ther. – 2013. – Vol. 16. – pp. 391–402.
15. Anderson J. Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer [Journal]//Future Oncol. – 2009. – Vol. 5. – pp. 433–43.
16. Persson B. E., Kold Olesen T., Jensen J. K. Degarelix: a new approach for the treatment of prostate cancer [Journal]//Neuroendocrinology. – 2009. – Vol. 90. – pp. 235–44.
17. Klotz L., Boccon-Gibod L., Shore N. D. et al. The efficacy and safety of degarelix: a 12‑month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. [Journal]//BJU Int. – 2008. – Vol. 102. – pp. 1531–8.
18. Crawford E. D., Shore N. D., Moul J. W. et al. Long-term tolerability and efficacy of degarelix: 5‑year results from a phase III extension trial with a 1‑arm crossover from leuprolide to degarelix [Journal]//Urology. – 2014. – Vol. 83. – pp. 1122–8.
19. Klotz L., Miller K., Crawford E. D. et al. Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomised Clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone Agonists [Journal]//Eur Urol. – 2014. – Vol. 66. – pp. 1101–8.
20. Kurt Miller, Christoph Rüssel, Sandra Goble et al. Open-label, exploratory study of degarelix as second-line hormonal therapy in patients with prostate cancer (CS27)//Poster 678. – [s. l.]: EAU, 2013.
21. Van Poppel H1, Klotz L. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists [Journal]//Int J Urol. – 2012. – Vol. 19. – pp. 594–601.
22. Smith M. R.1, Klotz L., van der Meulen E. et al. Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix [Journal]//J Urol. – 2011. – Vol. 186. – pp. 1835–42.
23. Tanriverdi F., Gonzalez-Martinez D., Hu Y. et al. GnRH-I and GnRHII have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin‑2 receptor gamma-chain mRNA expression in healthy males [Journal]//Clin Exp Immunol. – 2005. – Vol. 142. – pp. 103–10.
24. Chen H. F., Jeung E. B., Stephenson M., Leung P. C. Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin‑2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro [Journal]//J Clin Endocrinol Metab. – 1999. – Vol. 84. – pp. 743–50.
Review
For citations:
Nyushko K.M., Krasheninnikov A.A., Golovaschenko M.P., Kaprin A.D. HORMONE THERAPY WITH USAGE OF AGONISTS AND ANTAGONISTS OF LUTEINIZING HORMONE RELEASING HORMONE IN PATIENTS WITH PROSTATE CANCER. Research and Practical Medicine Journal. 2014;1(1):69-73. (In Russ.) https://doi.org/10.17709/2409-2231-2014-1-1-69-73
Views:
2475
Email this article 